Multifaceted polo-like kinases: drug targets and antitar

Nature Reviews Drug Discovery

9, 643-660

DOI: 10.1038/nrd3184

Citation Report

#	Article	IF	Citations
1	The substrates of Plk1, beyond the functions in mitosis. Protein and Cell, 2010, 1, 999-1010.	4.8	42
2	Cdk1/Cyclin B1 Controls Fas-Mediated Apoptosis by Regulating Caspase-8 Activity. Molecular and Cellular Biology, 2010, 30, 5726-5740.	1.1	80
3	Irreversible Nek2 Kinase Inhibitors with Cellular Activity. Journal of Medicinal Chemistry, 2011, 54, 4133-4146.	2.9	84
4	Mechanisms of drug resistance in kinases. Expert Opinion on Investigational Drugs, 2011, 20, 153-208.	1.9	157
5	Exploring Aigialomycin D and Its Analogues as Protein Kinase Inhibitors for Cancer Targets. ACS Medicinal Chemistry Letters, 2011, 2, 662-666.	1.3	26
6	Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors. Future Medicinal Chemistry, 2011, 3, 415-424.	1.1	37
7	Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective. ISRN Oncology, 2011, 2011, 1-13.	2.1	6
8	Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. Experimental Biology and Medicine, 2011, 236, 648-657.	1.1	34
9	RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. Journal of Clinical Bioinformatics, 2011, 1, 6.	1.2	16
10	Polo-Box Domain Inhibitor Poloxin Activates the Spindle Assembly Checkpoint and Inhibits Tumor Growth in Vivo. American Journal of Pathology, 2011, 179, 2091-2099.	1.9	78
11	Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits. Cell, 2011, 147, 853-867.	13.5	177
12	Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Review of Anticancer Therapy, 2011, 11, 1117-1132.	1.1	20
13	Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nature Chemical Biology, 2011, 7, 595-601.	3.9	96
14	Mitotic Spindle Proteomics in Chinese Hamster Ovary Cells. PLoS ONE, 2011, 6, e20489.	1.1	50
15	BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anti-Cancer Drugs, 2011, 22, 995-1001.	0.7	23
16	Gene signatures in hepatocellular carcinoma (HCC). Seminars in Cancer Biology, 2011, 21, 4-9.	4.3	47
17	Minicells: Versatile vectors for targeted drug or si/shRNA cancer therapy. Current Opinion in Biotechnology, 2011, 22, 909-916.	3.3	66
18	PLK1 as an oncology target: current status and future potential. Drug Discovery Today, 2011, 16, 619-625.	3.2	89

#	Article	IF	Citations
19	The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Experimental Hematology, 2011, 39, 330-338.	0.2	18
20	Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle progression and checkpoints. Cellular Signalling, 2011, 23, 2030-2038.	1.7	26
21	Investigation of Unanticipated Alkylation at the N(Ï€) Position of a Histidyl Residue Under Mitsunobu Conditions and Synthesis of Orthogonally Protected Histidine Analogues. Journal of Organic Chemistry, 2011, 76, 8885-8890.	1.7	22
22	Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clinical and Experimental Metastasis, 2011, 28, 899-908.	1.7	39
23	Plk1-Targeted Small Molecule Inhibitors: Molecular Basis for Their Potency and Specificity. Molecules and Cells, 2011, 32, 209-220.	1.0	52
24	Structureâ€Based Pharmacophores for Virtual Screening. Molecular Informatics, 2011, 30, 398-404.	1.4	28
25	Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology, 2011, 53, 1137-1147.	3.6	51
26	Oncogene addiction as a foundational rationale for targeted antiâ€cancer therapy: promises and perils. EMBO Molecular Medicine, 2011, 3, 623-636.	3.3	218
27	Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3066-3069.	1.0	14
28	NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2969-2974.	1.0	81
29	Growth and Metastases of Human Lung Cancer Are Inhibited in Mouse Xenografts by a Transition State Analogue of 5â€²-Methylthioadenosine Phosphorylase. Journal of Biological Chemistry, 2011, 286, 4902-4911.	1.6	60
30	New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opinion on Investigational Drugs, 2011, 20, 507-518.	1.9	52
31	Plk1 Phosphorylation of Orc2 Promotes DNA Replication under Conditions of Stress. Molecular and Cellular Biology, 2011, 31, 4844-4856.	1.1	58
32	Independent modulation of the kinase and polo-box activities of Cdc5 protein unravels unique roles in the maintenance of genome stability. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E914-23.	3.3	26
33	From Plk1 to Plk5. Cell Cycle, 2011, 10, 2255-2262.	1.3	227
34	Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells. Cancer Research, 2011, 71, 1385-1395.	0.4	92
35	Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation. Journal of Biological Chemistry, 2011, 286, 35795-35800.	1.6	57
36	Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nature Communications, 2011, 2, 395.	5.8	76

#	Article	IF	Citations
37	A MEK-independent role for CRAF in mitosis and tumor progression. Nature Medicine, 2011, 17, 1641-1645.	15.2	63
38	Combined Pharmacophore Modeling, Docking, and 3D-QSAR Studies of PLK1 Inhibitors. International Journal of Molecular Sciences, 2011, 12, 8713-8739.	1.8	19
39	Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy. Cell Death and Differentiation, 2012, 19, 1255-1267.	5.0	75
40	Polo-like kinase is required for synaptonemal complex disassembly and phosphorylation in mouse spermatocytes. Journal of Cell Science, 2012, 125, 5061-72.	1.2	87
41	NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Molecular Cancer Therapeutics, 2012, 11, 1006-1016.	1.9	87
42	Polo-like kinase 1 directs the AMPK-mediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance. Cell Cycle, 2012, 11, 2422-2426.	1.3	16
43	Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biology and Therapy, 2012, 13, 1214-1220.	1.5	10
44	Polo-like kinases in AML. Expert Opinion on Investigational Drugs, 2012, 21, 1069-1074.	1.9	11
45	A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naÃ¯ve patients with unresectable exocrine adenocarcinoma of the pancreas â€“ a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. British Journal of Cancer, 2012, 107, 280-286.	2.9	67
46	Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype. Molecular Cancer Therapeutics, 2012, 11, 1683-1692.	1.9	22
47	Plk1 Phosphorylates Sgt1 at the Kinetochores To Promote Timely Kinetochore-Microtubule Attachment. Molecular and Cellular Biology, 2012, 32, 4053-4067.	1.1	30
48	Mitotic Kinases and p53 Signaling. Biochemistry Research International, 2012, 2012, 1-14.	1.5	12
49	Identification of retinoblastoma related genes with shortest path in a proteinâ€“protein interaction network. Biochimie, 2012, 94, 1910-1917.	1.3	28
50	Quinazoline derivatives as potential anticancer agents: a patent review (2007 â€“ 2010). Expert Opinion on Therapeutic Patents, 2012, 22, 223-252.	2.4	104
51	PIM1 kinase as a target for cancer therapy. Expert Opinion on Investigational Drugs, 2012, 21, 425-436.	1.9	108
52	Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53mutation and poor clinical outcome. Breast Cancer Research, 2012, 14, R40.	2.2	82
53	Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels. Neoplasia, 2012, 14, 410-IN10.	2.3	45
54	Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2012, 16, 945-958.	1.5	28

#	Article	IF	Citations
55	Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break Repair. Molecular Cell, 2012, 45, 371-383.	4.5	141
56	Discrimination of genotoxic and non-genotoxic hepatocarcinogens by statistical analysis based on gene expression profiling in the mouse liver as determined by quantitative real-time PCR. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 747, 164-175.	0.9	37
57	Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer Cells. Stem Cells, 2012, 30, 1819-1830.	1.4	53
58	Integrating gene expression and protein-protein interaction network to prioritize cancer-associated genes. BMC Bioinformatics, 2012, 13, 182.	1.2	110
59	Polo-like kinase 1 (Plk1): an Unexpected Player in DNA Replication. Cell Division, 2012, 7, 3.	1.1	45
60	Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells. Oncogene, 2012, 31, 4946-4959.	2.6	38
61	Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7306-7308.	1.0	21
62	Reciprocal Activation Between PLK1 and Stat3 Contributes to Survival and Proliferation of Esophageal Cancer Cells. Gastroenterology, 2012, 142, 521-530.e3.	0.6	80
63	Investigation on PLK2 and PLK3 substrate recognition. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 1366-1373.	1.1	32
64	The SUMO protease SENP1 is required for cohesion maintenance and mitotic arrest following spindle poison treatment. Biochemical and Biophysical Research Communications, 2012, 426, 310-316.	1.0	13
65	Chemical Visualization of Phosphoproteomes on Membrane. Molecular and Cellular Proteomics, 2012, 11, 629-639.	2.5	26
66	Polo-like kinase 1 as target for cancer therapy. Experimental Hematology and Oncology, 2012, 1, 38.	2.0	73
67	Roles of Polo-like kinase 3 in suppressing tumor angiogenesis. Experimental Hematology and Oncology, 2012, 1, 5.	2.0	21
68	Targeting of polo-like kinases and their cross talk with Aurora kinases â€“ possible therapeutic strategies in human acute myeloid leukemia?. Expert Opinion on Investigational Drugs, 2012, 21, 587-603.	1.9	23
69	The Centrosomal Kinase Plk1 Localizes to the Transition Zone of Primary Cilia and Induces Phosphorylation of Nephrocystin-1. PLoS ONE, 2012, 7, e38838.	1.1	44
70	MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Letters, 2012, 317, 184-191.	3.2	76
71	Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition. Molecular Carcinogenesis, 2012, 51, 696-710.	1.3	11
72	Peptoidâ€“Peptide Hybrid Ligands Targeting the Polo Box Domain of Poloâ€Like Kinase 1. ChemBioChem, 2012, 13, 1291-1296.	1.3	38

#	Article	IF	Citations
73	Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Protein and Cell, 2012, 3, 182-197.	4.8	18
74	Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1247-1250.	1.0	33
75	5-(2-Amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 96-101.	1.0	16
76	Identification of Novel Poloâ€like Kinase 1 Inhibitors by a Hybrid Virtual Screening. Chemical Biology and Drug Design, 2012, 80, 328-339.	1.5	0
77	Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer, 2012, 12, 80.	1.1	69
78	Applications of Mass Spectrometry in Proteomics. Australian Journal of Chemistry, 2013, 66, 721.	0.5	30
79	Reptiles. Current Biology, 2013, 23, R227-R231.	1.8	20
80	Plk1â€dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate, 2013, 73, 1352-1363.	1.2	27
81	De novodesign of PLK1 inhibitors based on 2-amino aromatic heterocyclic scaffold: 3D-QSAR and molecular fragment replacement. Molecular Simulation, 2013, 39, 975-987.	0.9	1
82	The PLK1 Inhibitor GSK461364A Is Effective in Poorly Differentiated and Anaplastic Thyroid Carcinoma Cells, Independent of the Nature of Their Driver Mutations. Thyroid, 2013, 23, 1284-1293.	2.4	30
83	Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Therapy, 2013, 20, 499-506.	2.2	54
84	Analysis of Plk1-Bora interaction using a protein chip system. Biochip Journal, 2013, 7, 151-155.	2.5	3
85	p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53â€“E2F1â€“DNA complex. Experimental Cell Research, 2013, 319, 3104-3115.	1.2	29
87	Endothelial Microparticleâ€“Mediated Transfer of MicroRNA-126 Promotes Vascular Endothelial Cell Repair via SPRED1 and Is Abrogated in Glucose-Damaged Endothelial Microparticles. Circulation, 2013, 128, 2026-2038.	1.6	391
88	The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?. Cancer Research, 2013, 73, 6848-6855.	0.4	111
89	Drugs by Numbers: Reactionâ€Driven De Novo Design of Potent and Selective Anticancer Leads. Angewandte Chemie - International Edition, 2013, 52, 4676-4681.	7.2	22
91	Polo-like kinases. Current Biology, 2013, 23, R225-R227.	1.8	8
92	Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecologic Oncology, 2013, 128, 461-469.	0.6	29

#	Article	IF	Citations
93	Tumour selective targeting of cell cycle kinases for cancer treatment. Current Opinion in Pharmacology, 2013, 13, 529-535.	1.7	65
94	Tid1/Rdh54 translocase is phosphorylated through a Mec1- and Rad53-dependent manner in the presence of DSB lesions in budding yeast. DNA Repair, 2013, 12, 347-355.	1.3	18
95	Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. Bioorganic and Medicinal Chemistry, 2013, 21, 3996-4003.	1.4	18
96	Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2743-2749.	1.0	25
97	Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. European Journal of Cancer, 2013, 49, 3020-3028.	1.3	51
98	Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators. Journal of Medicinal Chemistry, 2013, 56, 5219-5230.	2.9	104
99	Acidic pHâ€Responsive siRNA Conjugate for Reversible Carrier Stability and Accelerated Endosomal Escape with Reduced IFNÎ±â€Associated Immune Response. Angewandte Chemie - International Edition, 2013, 52, 6218-6221.	7.2	103
100	Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle, 2013, 12, 1340-1351.	1.3	29
101	Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene, 2013, 32, 2973-2983.	2.6	65
102	Selective and Brainâ€Permeable Poloâ€like Kinaseâ€2 (Plkâ€2) Inhibitors That Reduce Î±â€Synuclein Phosphorylation in Rat Brain. ChemMedChem, 2013, 8, 1295-1313.	1.6	43
103	Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials, 2013, 34, 3411-3421.	5.7	88
104	Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. Expert Opinion on Investigational Drugs, 2013, 22, 635-661.	1.9	9
105	Plk1: unexpected roles in DNA replication. Cell Research, 2013, 23, 1251-1253.	5.7	33
106	Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology, 2013, 58, 1362-1374.	3.6	37
107	FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Biology Open, 2013, 2, 1022-1031.	0.6	18
108	Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes. Cell Research, 2013, 23, 1284-1295.	5.7	27
109	Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstetrics and Gynecology International, 2013, 2013, 1-10.	0.5	25
110	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. PLoS Computational Biology, 2013, 9, e1003290.	1.5	128

#	Article	IF	Citations
111	Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anti-Cancer Drugs, 2013, 24, 999-1006.	0.7	82
112	Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer. Cancer Research, 2013, 73, 813-823.	0.4	182
113	Downregulation of Polo-Like Kinase 1 Induces Cellular Senescence in Human Primary Cells Through a p53-Dependent Pathway. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 1145-1156.	1.7	23
114	Inhibition of Polo-Like Kinase 1 Induces Cell Cycle Arrest and Sensitizes Glioblastoma Cells to Ionizing Radiation. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 516-522.	0.7	25
115	Identification of potent virtual leads to design novel PLK1 inhibitors: pharmacophore modelling, virtual screening and molecular docking studies. Molecular Simulation, 2013, 39, 640-652.	0.9	1
116	A randomized, openâ€label, phase I/II trial to investigate the maximum tolerated dose of the <scp>P</scp>oloâ€like kinase inhibitor <scp>BI</scp> 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. British Journal of Haematology, 2013, 163, 214-222.	1.2	36
117	In vitro targeting of Polo-like kinase 1 in bladder carcinoma. Cancer Biology and Therapy, 2013, 14, 648-657.	1.5	29
118	BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress. Cell Cycle, 2013, 12, 2255-2265.	1.3	23
119	Structural basis for the inhibition of Polo-like kinase 1. Nature Structural and Molecular Biology, 2013, 20, 1047-1053.	3.6	93
120	Ubiquitylation-dependent localization of PLK1 in mitosis. Nature Cell Biology, 2013, 15, 430-439.	4.6	91
121	Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death and Disease, 2013, 4, e925-e925.	2.7	40
122	Targeting prostate cancer cell lines with poloâ€like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB Journal, 2013, 27, 4279-4293.	0.2	29
124	Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck. Molecular and Clinical Oncology, 2013, 1, 286-290.	0.4	7
125	A High-Content Small Molecule Screen Identifies Sensitivity of Glioblastoma Stem Cells to Inhibition of Polo-Like Kinase 1. PLoS ONE, 2013, 8, e77053.	1.1	53
126	Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology American Society of Hematology Education Program, 2014, 2014, 34-43.	0.9	2
127	Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1. Amino Acids, 2014, 46, 2595-2603.	1.2	13
128	Pin1-mediated Sp1 phosphorylation by CDK1 increases Sp1 stability and decreases its DNA-binding activity during mitosis. Nucleic Acids Research, 2014, 42, 13573-13587.	6.5	19
129	The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers. Cell Cycle, 2014, 13, 1413-1423.	1.3	28

#	Article	IF	Citations
130	Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells. Cell Research, 2014, 24, 1141-1145.	5.7	19
131	Targeting Echinococcus multilocularis Stem Cells by Inhibition of the Polo-Like Kinase EmPlk1. PLoS Neglected Tropical Diseases, 2014, 8, e2870.	1.3	45
132	Mechanisms Underlying Plk1 Polo-Box Domain-Mediated Biological Processes and Their Physiological Significance. Molecules and Cells, 2014, 37, 286-294.	1.0	20
133	Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology American Society of Hematology Education Program, 2014, 2014, 34-43.	0.9	27
134	Polo kinase regulates the localization and activity of the chromosomal passenger complex in meiosis and mitosis in Drosophila melanogaster. Open Biology, 2014, 4, 140162.	1.5	14
135	Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State. Molecular and Cellular Biology, 2014, 34, 3642-3661.	1.1	69
136	RNAi Screen Identifies a Synthetic Lethal Interaction between PIM1 Overexpression and PLK1 Inhibition. Clinical Cancer Research, 2014, 20, 3211-3221.	3.2	18
137	Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Investigational New Drugs, 2014, 32, 1167-1180.	1.2	28
138	Mutant TP53 Posttranslational Modifications: Challenges and Opportunities. Human Mutation, 2014, 35, 738-755.	1.1	60
139	An openâ€label, singleâ€arm, phase 2 trial of the poloâ€like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer, 2014, 120, 976-982.	2.0	75
140	Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na. Molecular Cancer Therapeutics, 2014, 13, 1054-1066.	1.9	6
141	CLIP-170 is required to recruit PLK1 to kinetochores during early mitosis for chromosome alignment. Journal of Cell Science, 2014, 127, 2818-24.	1.2	29
142	Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies. Clinical Cancer Research, 2014, 20, 1656-1665.	3.2	58
143	SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment. Biomaterials, 2014, 35, 6519-6533.	5.7	60
144	Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. , 2014, 142, 258-269.		75
145	PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule. Radiotherapy and Oncology, 2014, 110, 355-361.	0.3	30
146	Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell, 2014, 25, 304-317.	7.7	1,226
147	Phosphorylation of p300 increases its protein degradation to enhance the lung cancer progression. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1135-1149.	1.9	27

#	Article	IF	Citations
148	Disarming mutant p53 oncogenic function. Pharmacological Research, 2014, 79, 75-87.	3.1	20
149	Target validation using in-cell small molecule clickable imaging probes. MedChemComm, 2014, 5, 247-254.	3.5	24
150	Mitogen-Activated Protein Kinaseâ€“Activated Protein Kinase 2 in Neuroinflammation, Heat Shock Protein 27 Phosphorylation, and Cell Cycle: Role and Targeting. Molecular Pharmacology, 2014, 85, 345-356.	1.0	73
151	Plk1 Protein Phosphorylates Phosphatase and Tensin Homolog (PTEN) and Regulates Its Mitotic Activity during the Cell Cycle. Journal of Biological Chemistry, 2014, 289, 14066-14074.	1.6	43
152	Mass Spectrometry for Proteomics-Based Investigation. Advances in Experimental Medicine and Biology, 2014, 806, 1-32.	0.8	16
153	Signal Transduction: From the Atomic Age to the Post-Genomic Era. Cold Spring Harbor Perspectives in Biology, 2014, 6, a022913-a022913.	2.3	21
154	A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. British Journal of Cancer, 2014, 110, 2434-2440.	2.9	65
155	Polo-like Kinase 2, a Novel ADAM17 Signaling Component, Regulates Tumor Necrosis Factor Î± Ectodomain Shedding. Journal of Biological Chemistry, 2014, 289, 3080-3093.	1.6	45
156	Self-assembling doxorubicin-prodrug nanoparticles as siRNA drug delivery system for cancer treatment: in vitro and in vivo. Journal of Materials Chemistry B, 2014, 2, 5910-5924.	2.9	23
157	Compound library screening identified Akt/PKB kinase pathway inhibitors as potential key molecules for the development of new chemotherapeutics against schistosomiasis. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 256-266.	1.4	31
158	PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2014, 61, 1227-1231.	0.8	12
159	Vanillin-derived antiproliferative compounds influence Plk1 activity. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5063-5069.	1.0	14
160	Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer. Cancer Research, 2014, 74, 6635-6647.	0.4	87
161	Improvement of Doxorubicin Efficacy Using Liposomal Anti-Polo-like Kinase 1 siRNA in Human Renal Cell Carcinomas. Molecular Pharmaceutics, 2014, 11, 2713-2719.	2.3	41
162	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncology, 2014, 10, 1157-1165.	1.1	22
163	Synthesis and antitumor activity evaluation of anilinoquinoline derivatives by the effect on the expression of polo-like kinase. Medicinal Chemistry Research, 2014, 23, 1437-1446.	1.1	2
164	Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorganic and Medicinal Chemistry, 2014, 22, 5050-5059.	1.4	204
165	Sequential Cdk1 and Plk1 phosphorylation of caspaseâ€8 triggers apoptotic cell death during mitosis. Molecular Oncology, 2014, 8, 596-608.	2.1	55

#	Article	IF	Citations
166	Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction. Free Radical Biology and Medicine, 2014, 73, 270-277.	1.3	37
167	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood, 2014, 124, 1426-1433.	0.6	204
168	Monoâ€anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 poloâ€box domainâ€binding affinities and enhanced antiproliferative effects in hela cells. Biopolymers, 2014, 102, 444-455.	1.2	24
169	Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells. Molecular Medicine Reports, 2015, 11, 3033-3038.	1.1	10
170	Phase I trial of volasertib, a Poloâ€like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Cancer Science, 2015, 106, 1590-1595.	1.7	37
171	Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. International Journal of Molecular Sciences, 2015, 16, 26706-26720.	1.8	65
172	Identification of Green Tea Catechins as Potent Inhibitors of the Poloâ€Box Domain of Poloâ€Like kinaseâ€...1. ChemMedChem, 2015, 10, 158-163.	1.6	25
173	Poloâ€like kinase 3 is associated with improved overall survival in cholangiocarcinoma. Liver International, 2015, 35, 2448-2457.	1.9	7
174	Structural analysis of the poloâ€box domain of human Poloâ€like kinase 2. Proteins: Structure, Function and Bioinformatics, 2015, 83, 1201-1208.	1.5	9
175	Volasertib for AML: clinical use and patient consideration. OncoTargets and Therapy, 2015, 8, 1761.	1.0	13
176	Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis. Frontiers in Oncology, 2015, 5, 241.	1.3	1
177	PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. BioMed Research International, 2015, 2015, 1-21.	0.9	44
178	Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. Journal of Investigative Dermatology, 2015, 135, 2475-2483.	0.3	51
179	Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Cell Death and Differentiation, 2015, 22, 1946-1956.	5.0	48
180	A phase I study of volasertib combined with afatinib, in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 843-851.	1.1	19
181	Plk1 and Mps1 Cooperatively Regulate the Spindle Assembly Checkpoint in Human Cells. Cell Reports, 2015, 12, 66-78.	2.9	96
182	Crystal structure of the polo-box domain of polo-like kinase 2. Biochemical and Biophysical Research Communications, 2015, 456, 780-784.	1.0	9
183	Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Cancer Letters, 2015, 357, 591-601.	3.2	45

#	Article	IF	Citations
184	Understanding the Polo Kinase machine. Oncogene, 2015, 34, 4799-4807.	2.6	127
185	Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 579-589.	1.3	57
186	PLK1 Inhibition Down-regulates Polycomb Group Protein BMI1 via Modulation of the miR-200c/141 Cluster. Journal of Biological Chemistry, 2015, 290, 3033-3044.	1.6	21
187	Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer. Journal of Biological Chemistry, 2015, 290, 2024-2033.	1.6	34
188	Identification of Rictor as a Novel Substrate of Polo-like kinase 1. Cell Cycle, 2015, 14, 755-760.	1.3	7
189	Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes. Biomaterials Science, 2015, 3, 1114-1123.	2.6	40
190	Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Cancer Letters, 2015, 365, 37-46.	3.2	25
191	The Catalytic Subunit of DNA-Dependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry. Neoplasia, 2015, 17, 329-338.	2.3	13
192	A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 457-465.	1.1	41
193	Plk1 Phosphorylation of IRS2 Prevents Premature Mitotic Exit via AKT Inactivation. Biochemistry, 2015, 54, 2473-2480.	1.2	12
194	Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. Investigational New Drugs, 2015, 33, 611-620.	1.2	20
195	Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle, 2015, 14, 2142-2148.	1.3	21
196	PLK4 Is Essential for Meiotic Resumption in Mouse Oocytes1. Biology of Reproduction, 2015, 92, 101.	1.2	15
197	Targeting polo-like kinase 1 in acute myeloid leukemia. Therapeutic Advances in Hematology, 2015, 6, 80-87.	1.1	30
198	Re-positioning protein-kinase inhibitors against schistosomiasis. Future Medicinal Chemistry, 2015, 7, 737-752.	1.1	28
199	A synthesis, in silico, in vitro and in vivo study of thieno[2,3-b]pyridine anticancer analogues. MedChemComm, 2015, 6, 1987-1997.	3.5	39
200	Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics, 2015, 12, 3885-3895.	2.3	31
201	Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activityâ€“dependent suicidal inhibition of its polo-box domain. Cell Cycle, 2015, 14, 3624-3634.	1.3	9

#	Article	IF	Citations
202	Polo-like kinase 2 regulates angiogenic sprouting and blood vessel development. Developmental Biology, 2015, 404, 49-60.	0.9	14
203	Putting a bit into the polo-box domain of polo-like kinase 1. Journal of Analytical Science and Technology, 2015, 6, 27.	1.0	5
204	Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Translational Oncology, 2015, 8, 185-195.	1.7	145
205	Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression. Cell Cycle, 2015, 14, 3101-3111.	1.3	10
206	Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells. ACS Chemical Biology, 2015, 10, 2570-2579.	1.6	53
207	Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1). Cell Cycle, 2015, 14, 3030-3039.	1.3	17
208	Playing Polo-Like Kinase in NRAS-Mutant Melanoma. Journal of Investigative Dermatology, 2015, 135, 2352-2355.	0.3	6
209	Targeting Mitosis in Cancer: Emerging Strategies. Molecular Cell, 2015, 60, 524-536.	4.5	384
210	New treatment for acute myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2015, 16, 95-106.	0.9	26
211	Less understood issues: p21Cip1 in mitosis and its therapeutic potential. Oncogene, 2015, 34, 1758-1767.	2.6	90
212	Novel drugs for older patients with acute myeloid leukemia. Leukemia, 2015, 29, 760-769.	3.3	65
213	Mitotic arrest and slippage induced by pharmacological inhibition of Poloâ€like kinase 1. Molecular Oncology, 2015, 9, 140-154.	2.1	47
214	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia, 2015, 29, 11-19.	3.3	171
215	Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy. International Journal of Nanomedicine, 2016, Volume 11, 5277-5286.	3.3	39
216	Structure-Based Ligand Design II. , 2016, , 61-108.		0
217	Structure-Based Ligand Design I. , 2016, , 15-60.		1
218	Novel N-Substituted 2-(2-(Adamantan-1-yl)-1H-Indol-3-yl)-2-Oxoacetamide Derivatives: Synthesis and Biological Evaluation. Molecules, 2016, 21, 530.	1.7	2
219	Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks. BioMed Research International, 2016, 2016, 1-9.	0.9	36

#	Article	IF	Citations
220	Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni. PLoS Neglected Tropical Diseases, 2016, 10, e0004356.	1.3	56
221	Polo-Like Kinase 3 Appears Dispensable for Normal Retinal Development Despite Robust Embryonic Expression. PLoS ONE, 2016, 11, e0150878.	1.1	1
222	Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget, 2016, 7, 57633-57650.	0.8	88
223	Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. Cell Research, 2016, 26, 914-934.	5.7	35
224	Inhibitors of the Poloâ€Box Domain of Poloâ€Like Kinase 1. ChemBioChem, 2016, 17, 650-656.	1.3	24
225	Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Medicinal Research Reviews, 2016, 36, 749-786.	5.0	78
226	Synergistic induction of apoptosis by a poloâ€like kinase 1 inhibitor and microtubuleâ€interfering drugs in <scp>E</scp>wing sarcoma cells. International Journal of Cancer, 2016, 138, 497-506.	2.3	26
227	Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. Molecular Cancer Therapeutics, 2016, 15, 2107-2118.	1.9	39
228	Molecular interactions of polo-like kinase 1 in human cancers. Journal of Clinical Pathology, 2016, 69, 557-562.	1.0	25
229	Functional analysis of ZFP36 proteins in keratinocytes. European Journal of Cell Biology, 2016, 95, 277-284.	1.6	23
230	Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. Oncology Reports, 2016, 36, 49-56.	1.2	55
231	Molecular insight into the regulation and function of MCAK. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 228-245.	2.3	36
232	RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 1198-1217.	0.9	68
233	Tumor suppressor protein DAB2IP participates in chromosomal stability maintenance through activating spindle assembly checkpoint and stabilizing kinetochore-microtubule attachments. Nucleic Acids Research, 2016, 44, 8842-8854.	6.5	18
234	Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5009-5012.	1.0	17
235	Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies. Inside the Cell, 2016, 1, 59-69.	0.4	0
236	Reduced kinase activity of polo kinase Cdc5 affects chromosome stability and DNA damage response inS. cerevisiae. Cell Cycle, 2016, 15, 2906-2919.	1.3	16
237	The phosphorylation-dependent regulation of nuclear SREBP1 during mitosis links lipid metabolism and cell growth. Cell Cycle, 2016, 15, 2753-2765.	1.3	36

#	Article	IF	Citations
238	MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells. Biochemical and Biophysical Research Communications, 2016, 478, 676-682.	1.0	23
239	Polo-like KinaseÂ1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. BMC Cancer, 2016, 16, 647.	1.1	31
240	Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Scientific Reports, 2016, 6, 37581.	1.6	19
241	Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells. Journal of Medicinal Chemistry, 2016, 59, 7089-7096.	2.9	15
242	Genetic depletion of Poloâ€like kinase 1 leads to embryonic lethality due to mitotic aberrancies. BioEssays, 2016, 38, S96-S106.	1.2	19
243	Inhibition of cell proliferation and triggering of apoptosis by agrimonolide through MAP kinase (ERK) Tj ETQq1 1 0.784314 rgBT /Over	2.1	35
244	Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. International Journal of Pharmaceutics, 2016, 514, 24-40.	2.6	51
245	Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Molecular Cell, 2016, 64, 493-506.	4.5	123
246	A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes. BMC Systems Biology, 2016, 10, 71.	3.0	9
247	Development of Bifunctional Inhibitors of Poloâ€Like Kinaseâ€…1 with Lowâ€Nanomolar Activities Against the Poloâ€Box Domain. ChemBioChem, 2016, 17, 759-767.	1.3	20
248	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. Oncogene, 2016, 35, 6330-6340.	2.6	74
249	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 66-74.	1.2	15
250	Discovery of Nonâ€ATPâ€Competitive Inhibitors of Poloâ€like Kinaseâ€…1. ChemMedChem, 2016, 11, 713-717.	1.6	8
251	Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer. Cell Cycle, 2016, 15, 711-719.	1.3	28
252	PLK-1: Angel or devil for cell cycle progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 190-203.	3.3	34
253	Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells. Immunologic Research, 2016, 64, 687-698.	1.3	4
254	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). Bioorganic and Medicinal Chemistry, 2016, 24, 521-544.	1.4	21
255	Polo-like kinase inhibitors in hematologic malignancies. Critical Reviews in Oncology/Hematology, 2016, 98, 200-210.	2.0	29

#	Article	IF	Citations
256	In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach. Journal of Theoretical Biology, 2016, 388, 72-84.	0.8	8
257	The role of Plk3 in oncogenesis. Oncogene, 2016, 35, 135-147.	2.6	79
258	PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy, 2017, 13, 486-505.	4.3	63
259	DNA Damage Response-Independent Role for MDC1 in Maintaining Genomic Stability. Molecular and Cellular Biology, 2017, 37, .	1.1	11
260	Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. British Journal of Cancer, 2017, 116, 1027-1036.	2.9	26
261	PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. Child's Nervous System, 2017, 33, 609-615.	0.6	15
262	Synthesis of biaryl-linked cyclic peptoids. Tetrahedron Letters, 2017, 58, 1010-1014.	0.7	14
263	Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors. European Journal of Pharmaceutical Sciences, 2017, 104, 273-292.	1.9	86
264	CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression. Journal of Neuro-Oncology, 2017, 133, 87-95.	1.4	24
265	Poloâ€likeâ€kinase 1 is a proviral host factor for hepatitis B virus replication. Hepatology, 2017, 66, 1750-1765.	3.6	60
266	Playing polo during mitosis: PLK1 takes the lead. Oncogene, 2017, 36, 4819-4827.	2.6	140
267	MicroRNA-146a Induces Lineage-Negative Bone Marrow Cell Apoptosis and Senescence by Targeting Polo-Like Kinase 2 Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 280-290.	1.1	40
268	Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs. Advanced Drug Delivery Reviews, 2017, 115, 82-97.	6.6	64
269	Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response. Cancer Research, 2017, 77, 3169-3180.	0.4	45
270	Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell, 2017, 32, 57-70.e3.	7.7	324
271	Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. ACS Chemical Biology, 2017, 12, 1883-1892.	1.6	57
272	Phosphorylation of DEPDC1 at Ser110 is required to maintain centrosome organization during mitosis. Experimental Cell Research, 2017, 358, 101-110.	1.2	16
273	Microtubule Targeting Agents in Cancer Therapy: Elucidating the Underlying Molecular Mechanisms. , 2017, , 15-65.		4

#	Article	IF	Citations
274	Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. Bioorganic and Medicinal Chemistry, 2017, 25, 5041-5049.	1.4	14
275	Single nucleotide polymorphisms rs911160 in AURKA and rs2289590 in AURKB mitotic checkpoint genes contribute to gastric cancer susceptibility. Environmental and Molecular Mutagenesis, 2017, 58, 701-711.	0.9	9
276	PLK1-Targeted Fluorescent Tumor Imaging with High Signal-to-Background Ratio. ACS Sensors, 2017, 2, 1512-1516.	4.0	20
277	Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice. Journal of Biological Chemistry, 2017, 292, 17461-17472.	1.6	23
278	5-Ene-4-thiazolidinones â€“ An efficient tool in medicinal chemistry. European Journal of Medicinal Chemistry, 2017, 140, 542-594.	2.6	129
279	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. Expert Opinion on Emerging Drugs, 2017, 22, 213-222.	1.0	6
280	Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. International Journal of Pharmaceutics, 2017, 529, 506-522.	2.6	95
281	Identification of altered pathways in breast cancer based on individualized pathway aberrance score. Oncology Letters, 2017, 14, 1287-1294.	0.8	4
282	The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation. Scientific Reports, 2017, 7, 16115.	1.6	27
283	Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway. Nature Communications, 2017, 8, 1506.	5.8	100
284	Frameshift mutation and loss of expression of PLK2 , a serine/threonine kinase-encoding gene, in colorectal cancers. Pathology Research and Practice, 2017, 213, 1019-1020.	1.0	4
285	RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients. Journal of Controlled Release, 2017, 261, 199-206.	4.8	17
286	Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives. Clinical Colorectal Cancer, 2017, 16, 1-8.	1.0	16
287	<scp>NCAPG</scp>2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma. Journal of Cellular and Molecular Medicine, 2017, 21, 665-676.	1.6	41
288	Designed inhibitor for nuclear localization signal of poloâ€like kinase 1 induces mitotic arrest. Chemical Biology and Drug Design, 2017, 89, 732-740.	1.5	5
289	Sensitivity of TP53â€Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity. Journal of Cellular Physiology, 2017, 232, 2818-2828.	2.0	21
290	Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer. Biological and Pharmaceutical Bulletin, 2017, 40, 1454-1462.	0.6	3
291	Theoretical studies on benzimidazole and imidazo[1,2-a]pyridine derivatives as Polo-like kinase 1 (Plk1) inhibitors: Pharmacophore modeling, atom-based 3D-QSAR and molecular docking approach. Journal of Saudi Chemical Society, 2017, 21, S311-S321.	2.4	11

#	Article	IF	Citations
292	Recent Advances on Nucleotide Analogs and Mimetics. , 2017, , .		2
293	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. Journal of Cancer, 2017, 8, 1441-1452.	1.2	11
294	Anthocyanin-rich blackcurrant extract inhibits proliferation of the MCF10A healthy human breast epithelial cell line through induction of G0/G1 arrest and apoptosis. Molecular Medicine Reports, 2017, 16, 6134-6141.	1.1	13
295	Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. Oncotarget, 2017, 8, 97290-97303.	0.8	15
296	Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia. Oncotarget, 2017, 8, 78452-78465.	0.8	13
297	PLK4: a link between centriole biogenesis and cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 59-73.	1.5	53
298	Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling. Neoplasia, 2018, 20, 244-255.	2.3	18
299	BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. Scientific Reports, 2018, 8, 3521.	1.6	30
300	Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamideâ€“Hoechst Conjugate Suppresses Tumor Growth In Vivo. Molecular Cancer Therapeutics, 2018, 17, 988-1002.	1.9	13
301	Recent Advances in the Synthesis of Peptoid Macrocycles. Chemistry - A European Journal, 2018, 24, 7560-7573.	1.7	65
302	Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling. Cell Death and Disease, 2018, 9, 17.	2.7	88
303	PLK1 protects against sepsis-induced intestinal barrier dysfunction. Scientific Reports, 2018, 8, 1055.	1.6	21
304	Enhanced Intracellular Delivery of siRNA by Controlling ATPâ€Responsivity of Phenylboronic Acidâ€Functionalized Polyion Complex Micelles. Macromolecular Bioscience, 2018, 18, 1700357.	2.1	34
305	The rocky road to personalized medicine in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 2018, 22, 1411-1427.	1.6	15
306	Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2018, 17, 1554-1565.	1.9	35
307	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer, 2018, 18, 136.	1.1	13
308	<scp>T</scp>he <scp>TSC</scp>1â€m<scp>TOR</scp>â€PLK</scp> axis regulates the homeostatic switch from <scp>S</scp>chwann cell proliferation to myelination in a stageâ€specific manner. Glia, 2018, 66, 1947-1959.	2.5	10
309	Advances in kinome research of parasitic worms - implications for fundamental research and applied biotechnological outcomes. Biotechnology Advances, 2018, 36, 915-934.	6.0	8

#	Article	IF	Citations
310	Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin. Cancer Research, 2018, 78, 2864-2875.	0.4	17
311	PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nature Communications, 2018, 9, 1106.	5.8	47
312	Emerging therapeutic targets for the treatment of malignant rhabdoid tumors. Expert Opinion on Therapeutic Targets, 2018, 22, 365-379.	1.5	46
313	AGC kinases, mechanisms of regulation â€Žand innovative drug development. Seminars in Cancer Biology, 2018, 48, 1-17.	4.3	103
314	Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer. Biochemistry and Cell Biology, 2018, 96, 317-325.	0.9	10
315	Plk1 phosphorylation of Numb leads to impaired DNA damage response. Oncogene, 2018, 37, 810-820.	2.6	17
316	Chronic low dose arsenic exposure preferentially perturbs mitotic phase of the cell cycle. Genes and Cancer, 2018, 10, 39-51.	0.6	12
317	Selective Degradation of Poloâ€like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Poloâ€Box Domain. Angewandte Chemie, 2018, 130, 17289-17293.	1.6	3
318	PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Letters, 2018, 439, 56-65.	3.2	18
319	Selective Degradation of Poloâ€like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Poloâ€Box Domain. Angewandte Chemie - International Edition, 2018, 57, 17043-17047.	7.2	24
320	YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death and Disease, 2018, 9, 1066.	2.7	38
321	Recent insights into the development of nucleic acid-based nanoparticles for tumor-targeted drug delivery. Colloids and Surfaces B: Biointerfaces, 2018, 172, 315-322.	2.5	24
322	Molecular therapy using siRNA: Recent trends and advances of multi target inhibition of cancer growth. International Journal of Biological Macromolecules, 2018, 116, 880-892.	3.6	39
323	Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 3429-3437.	1.4	5
324	A PIM-CHK1 signaling pathway regulates PLK1 phosphorylation and function during mitosis. Journal of Cell Science, 2018, 131, .	1.2	7
325	Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma. Journal of Molecular Medicine, 2018, 96, 807-817.	1.7	11
326	Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds. ACS Chemical Biology, 2018, 13, 1921-1931.	1.6	12
327	Endothelial Cell Aging: How miRNAs Contribute?. Journal of Clinical Medicine, 2018, 7, 170.	1.0	25

#	Article	IF	Citations
328	Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma. Translational Oncology, 2018, 11, 852-863.	1.7	30
329	Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents. International Journal of Biological Macromolecules, 2018, 116, 173-181.	3.6	79
330	Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Letters, 2018, 436, 1-9.	3.2	18
331	A practical chromatography-free synthesis of a 5,6-dihydroimidazolo[1,5-f]pteridine derivative as a polo-like kinase-1 inhibitor. Tetrahedron, 2018, 74, 5779-5790.	1.0	1
332	miRâ€‘23a suppresses pancreatic cancer cell progression by inhibiting PLKâ€‘1 expression. Molecular Medicine Reports, 2018, 18, 105-112.	1.1	15
333	New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy. Annual Review of Pharmacology and Toxicology, 2019, 59, 361-377.	4.2	23
334	Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets. Epigenomics, 2019, 11, 1323-1333.	1.0	8
335	Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents. Journal of Medicinal Chemistry, 2019, 62, 7697-7707.	2.9	10
336	Stimuli-Responsive Polymerâ€“Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy. Nano Letters, 2019, 19, 5967-5974.	4.5	101
337	Enhanced polo-like kinase 1 expression in myelodysplastic syndromes. Blood Research, 2019, 54, 102-107.	0.5	0
338	Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells. Scientific Reports, 2019, 9, 10462.	1.6	17
339	Mass Spectrometry for Proteomics-Based Investigation. Advances in Experimental Medicine and Biology, 2019, 1140, 1-26.	0.8	18
340	Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1. Bioorganic Chemistry, 2019, 91, 103148.	2.0	1
341	The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2019, 60, 3214-3224.	0.6	2
342	Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold. European Journal of Medicinal Chemistry, 2019, 184, 111769.	2.6	13
343	A cis â€eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma. Cancer Medicine, 2019, 8, 6476-6484.	1.3	11
344	Oncogenic MYC amplifies mitotic perturbations. Open Biology, 2019, 9, 190136.	1.5	29
345	The role of aurora A and polo-like kinases in high-risk lymphomas. Blood Advances, 2019, 3, 1778-1787.	2.5	15

#	Article	IF	Citations
346	Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. Frontiers in Oncology, 2019, 9, 742.	1.3	5
347	Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis. Gene, 2019, 721, 144097.	1.0	10
348	Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells. Scientific Reports, 2019, 9, 13168.	1.6	3
349	Characterization and risk association of polymorphisms in Aurora kinases A, B and C with genetic susceptibility to gastric cancer development. BMC Cancer, 2019, 19, 919.	1.1	4
350	Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids. Molecules, 2019, 24, 3413.	1.7	5
351	Receptor-mediated delivery of therapeutic RNA by peptide functionalized curdlan nanoparticles. International Journal of Biological Macromolecules, 2019, 126, 633-640.	3.6	24
352	DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1. European Journal of Pharmacology, 2019, 847, 113-122.	1.7	2
353	Therapeutic potential of PLK1 inhibition in triple-negative breast cancer. Laboratory Investigation, 2019, 99, 1275-1286.	1.7	45
354	In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-Î²-Cyclodextrin Conjugate. AAPS Journal, 2019, 21, 54.	2.2	18
355	High Expression of Human AugminComplex Submit 3 Indicates Poor Prognosis and Associates with Tumor Progression in Hepatocellular Carcinoma. Journal of Cancer, 2019, 10, 1434-1443.	1.2	12
357	Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. Molecules, 2019, 24, 1488.	1.7	4
358	Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells. Organic and Biomolecular Chemistry, 2019, 17, 3113-3117.	1.5	13
359	InÂvitro study of the Poloâ€like kinase 1 inhibitor volasertib in nonâ€smallâ€cell lung cancer reveals a role for the tumor suppressor p53. Molecular Oncology, 2019, 13, 1196-1213.	2.1	17
360	Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Medicinal Research Reviews, 2019, 39, 1398-1426.	5.0	98
361	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers, 2019, 11, 1893.	1.7	7
362	Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS ONE, 2019, 14, e0224420.	1.1	36
363	Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. Journal of Pediatric Hematology/Oncology, 2019, 41, e359-e370.	0.3	0
364	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. Frontiers in Oncology, 2019, 9, 1271.	1.3	12

#	Article	IF	Citations
365	The methyltransferase SETD6 regulates Mitotic progression through PLK1 methylation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1235-1240.	3.3	31
366	Therapeutic potential of pteridine derivatives: A comprehensive review. Medicinal Research Reviews, 2019, 39, 461-516.	5.0	31
367	Effect of PLK1 inhibition on cisplatinâ€resistant gastric cancer cells. Journal of Cellular Physiology, 2019, 234, 5904-5914.	2.0	19
368	PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Letters, 2019, 443, 91-107.	3.2	43
369	Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy. Seminars in Cancer Biology, 2019, 56, 47-55.	4.3	25
370	PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3. Cancer Gene Therapy, 2020, 27, 412-423.	2.2	31
371	Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds. Investigational New Drugs, 2020, 38, 1-9.	1.2	6
372	The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells. Journal of the National Cancer Institute, 2020, 112, 356-368.	3.0	42
373	Application of the adverse outcome pathway framework to genotoxic modes of action. Environmental and Molecular Mutagenesis, 2020, 61, 114-134.	0.9	35
374	Design of curdlan-based pH-sensitive polymers with endosome buffering functionality for siRNA delivery. International Journal of Biological Macromolecules, 2020, 146, 773-780.	3.6	15
375	Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 ⁺ T cells ex vivo. Science Advances, 2020, 6, eaba1941.	4.7	16
376	Drug design and molecular docking simulations of Polo-like kinase 1 inhibitors based on QSAR study. New Journal of Chemistry, 2020, 44, 21134-21145.	1.4	5
377	Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1. Journal of Medicinal Chemistry, 2020, 63, 14087-14117.	2.9	15
378	MICROWAVE ASSISTED SYNTHESIS AND MOLECULAR MODELING STUDIES OF SOME NOVEL POLO-LIKE KINASE 1 INHIBITORS AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS. International Research Journal of Pharmacy, 2020, 11, 56-65.	0.0	0
379	Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models. Journal of Medicinal Chemistry, 2020, 63, 14905-14920.	2.9	16
380	The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression. Frontiers in Oncology, 2020, 10, 558932.	1.3	15
381	Centrosomal Localization of RXRÎ± Promotes PLK1 Activation and Mitotic Progression and Constitutes a Tumor Vulnerability. Developmental Cell, 2020, 55, 707-722.e9.	3.1	6
382	Discovery of Targeted Covalent Natural Products against PLK1 by Herb-Based Screening. Journal of Chemical Information and Modeling, 2020, 60, 4350-4358.	2.5	12

#	Article	IF	Citations
383	Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. International Journal of Pharmaceutics, 2020, 585, 119479.	2.6	23
384	Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127329.	1.0	11
385	Polo-like kinase 1 (Plk1) is a positive regulator of DNA replication in the Xenopus in vitro system. Cell Cycle, 2020, 19, 1817-1832.	1.3	7
386	YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects. Cancer Chemotherapy and Pharmacology, 2020, 86, 33-43.	1.1	9
387	Caspase-8: The double-edged sword. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188357.	3.3	97
388	Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2447-2460.	1.2	14
389	Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. European Journal of Medicinal Chemistry, 2020, 191, 112152.	2.6	31
390	Inhibition of urinary bladder cancer cell proliferation by silibinin. Environmental and Molecular Mutagenesis, 2020, 61, 445-455.	0.9	21
391	Distinct surfaces on Cdc5/PLK Polo-box domain orchestrate combinatorial substrate recognition during cell division. Scientific Reports, 2020, 10, 3379.	1.6	9
392	Detection and destruction of HER2â€positive cancer cells by Ultra Quenchbodyâ€siRNA complex. Biotechnology and Bioengineering, 2020, 117, 1259-1269.	1.7	17
393	Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets. Journal of Clinical Pathology, 2020, 73, 243-249.	1.0	32
394	Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality. Molecular Cancer Therapeutics, 2020, 19, 1221-1231.	1.9	15
395	Non-mitotic functions of polo-like kinases in cancer cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188467.	3.3	45
396	Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. European Journal of Medicinal Chemistry, 2021, 210, 112954.	2.6	41
397	Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications. Journal of Drug Targeting, 2021, 29, 168-184.	2.1	30
398	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal of Hematology, 2021, 113, 92-99.	0.7	13
399	Overexpression of PLK1 relieved the myocardial ischemia-reperfusion injury of rats through inducing the mitophagy and regulating the p-AMPK/FUNDC1 axis. Bioengineered, 2021, 12, 2676-2687.	1.4	31
400	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. Communications Biology, 2021, 4, 166.	2.0	19

#	Article	IF	Citations
402	Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and Its Implication in Cancer Therapy. Frontiers in Cell and Developmental Biology, 2021, 9, 646687.	1.8	11
403	The Role of Polycomb Group Protein BMI1 in DNA Repair and Genomic Stability. International Journal of Molecular Sciences, 2021, 22, 2976.	1.8	17
405	CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. Cancer Research, 2021, 81, 3121-3133.	0.4	12
406	Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell, 2021, 39, 466-479.	7.7	88
407	Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer. Current Medicinal Chemistry, 2021, 28, 1775-1795.	1.2	17
408	AR Splicing Variants and Resistance to AR Targeting Agents. Cancers, 2021, 13, 2563.	1.7	27
409	Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk. Protein and Peptide Letters, 2021, 28, 340-358.	0.4	0
410	Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer. Cells, 2021, 10, 1176.	1.8	11
411	Size- and Surface- Dual Engineered Small Polyplexes for Efficiently Targeting Delivery of siRNA. Molecules, 2021, 26, 3238.	1.7	4
412	Coâ€Targeting Plk1 and DNMT3a in Advanced Prostate Cancer. Advanced Science, 2021, 8, e2101458.	5.6	7
413	Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases. Molecular Oncology, 2022, 16, 219-249.	2.1	7
414	Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. Journal of Medicinal Chemistry, 2021, 64, 9916-9925.	2.9	9
415	Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination. PLoS Pathogens, 2021, 17, e1009764.	2.1	4
416	Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 641.	1.7	13
417	Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. Frontiers in Cell and Developmental Biology, 2021, 9, 714718.	1.8	0
418	Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme. Scientific Reports, 2021, 11, 17444.	1.6	2
419	Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS â€mutant cancer. EMBO Molecular Medicine, 2021, 13, e13193.	3.3	11
420	Polo-like kinase 1 (Plk1) regulates DNA replication origin firing and interacts with Rif1 in Xenopus. Nucleic Acids Research, 2021, 49, 9851-9869.	6.5	12

#	Article	IF	Citations
421	A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro-Oncology, 2022, 24, 414-426.	0.6	15
422	Drug Discovery and Target Identification against Schistosomiasis: A Reality Check on Progress and Future Prospects. Current Topics in Medicinal Chemistry, 2022, 22, 1595-1610.	1.0	5
424	Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochemical Pharmacology, 2021, 193, 114747.	2.0	71
425	Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2021, 225, 113768.	2.6	52
426	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. PLoS ONE, 2021, 16, e0245664.	1.1	5
427	Cytotoxicity and molecular docking analysis of racemolactone I, a new sesquiterpene lactone isolated from Inula racemosa. Pharmaceutical Biology, 2021, 59, 941-952.	1.3	8
428	Therapeutic inhibition of poloâ€like kinases in anaplastic thyroid cancer. Cancer Science, 2021, 112, 803-814.	1.7	4
429	Cooperation of p53 Mutations with Other Oncogenic Alterations in Cancer. Sub-Cellular Biochemistry, 2014, 85, 41-70.	1.0	10
430	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2020, 26, 6132-6140.	3.2	45
431	Radiation Induced DNA Damage, Repair and Therapeutics. , 2013, , 110-110.		2
432	Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Medical Science Monitor, 2012, 18, BR237-BR246.	0.5	57
433	Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. F1000Research, 2017, 6, 1024.	0.8	22
434	The Transcription Factor YY1 Is a Substrate for Polo-Like Kinase 1 at the G2/M Transition of the Cell Cycle. PLoS ONE, 2011, 6, e15928.	1.1	32
435	Î³-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers. PLoS ONE, 2012, 7, e38465.	1.1	24
436	A Series of Beta-Carboline Derivatives Inhibit the Kinase Activity of PLKs. PLoS ONE, 2012, 7, e46546.	1.1	33
437	Identification of the PLK2-Dependent Phosphopeptidome by Quantitative Proteomics. PLoS ONE, 2014, 9, e111018.	1.1	9
438	Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer. PLoS ONE, 2015, 10, e0129313.	1.1	40
439	Increased Expression of Phosphorylated Polo-Like Kinase 1 and Histone in Bypass Vein Graft and Coronary Arteries following Angioplasty. PLoS ONE, 2016, 11, e0147937.	1.1	11

#	Article	IF	Citations
440	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Endocrine-Related Cancer, 2019, 26, 727-738.	1.6	8
441	DNA damage checkpoint adaptation genes are required for division of cells harbouring eroded telomeres. Microbial Cell, 2015, 2, 394-405.	1.4	9
442	Schistosoma mansoni polo-like kinases and their function in control of mitosis and parasite reproduction. Anais Da Academia Brasileira De Ciencias, 2011, 83, 627-635.	0.3	16
443	Role of MicroRNAs in Progression and Recurrence of Early-Stage Lung Adenocarcinoma. Pulmonary Research and Respiratory Medicine: Open Journal, 2015, 2, 52-62.	1.0	1
444	Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease. Aging, 2011, 3, 846-851.	1.4	39
445	Caloric restriction induces heat shock response and inhibits B16F10 cell tumorigenesis both in vitro and in vivo. Aging, 2015, 7, 233-240.	1.4	6
446	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget, 2016, 7, 47998-48010.	0.8	21
447	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. Oncotarget, 2016, 7, 53339-53349.	0.8	12
448	Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget, 2013, 4, 958-971.	0.8	32
449	Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells. Oncotarget, 2016, 7, 84271-84285.	0.8	14
450	Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget, 2017, 8, 1234-1246.	0.8	20
451	Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget, 2017, 8, 3064-3071.	0.8	43
452	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget, 2017, 8, 6730-6741.	0.8	34
453	Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget, 2014, 5, 667-678.	0.8	34
454	Regulatory functional territory of PLK-1 and their substrates beyond mitosis. Oncotarget, 2017, 8, 37942-37962.	0.8	12
455	Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. Oncotarget, 2017, 8, 52445-52456.	0.8	8
456	Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: a systematic review and meta-analysis. Oncotarget, 2017, 8, 57723-57732.	0.8	15
457	Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis. Oncotarget, 2014, 5, 3130-3144.	0.8	31

#	Article	IF	Citations
458	SCFFBXW7Î± modulates the intra-S-phase DNA-damage checkpoint by regulating Polo like kinase-1 stability. Oncotarget, 2014, 5, 4370-4383.	0.8	20
459	ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines. Oncotarget, 2018, 9, 10920-10933.	0.8	2
460	Colorectal cancer cells require glycogen synthase kinase-3Î² for sustaining mitosis via translocated promoter region (TPR)-dynein interaction. Oncotarget, 2018, 9, 13337-13352.	0.8	22
461	Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics. Oncotarget, 2018, 9, 25842-25859.	0.8	24
462	The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1. Oncotarget, 2015, 6, 6641-6655.	0.8	20
463	Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. Oncotarget, 2015, 6, 6611-6626.	0.8	27
464	PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins. Oncotarget, 2015, 6, 8736-8749.	0.8	17
465	Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget, 2016, 7, 8700-8711.	0.8	14
466	Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target. Oncotarget, 2011, 2, 935-947.	0.8	66
467	RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget, 2016, 7, 9832-9843.	0.8	12
468	Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan. Oncotarget, 2016, 7, 15215-15229.	0.8	16
469	ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Oncotarget, 2016, 7, 17162-17181.	0.8	8
470	Inhibiting Cell Cycle Kinases in Cancer Therapy. , 2012, , 154-188.		1
471	Time-course Comparison of Gene Expression Profiles Induced by the Genotoxic Hepatocarcinogen, Chrysene, in the Mouse Liver. Genes and Environment, 2014, 36, 54-64.	0.9	7
472	Antiviral Activity of PLK1-Targeting siRNA Delivered by Lipid Nanoparticles in HBV-Infected Hepatocytes. Antiviral Therapy, 2020, 25, 151-162.	0.6	7
473	Exploration of Mutation and DNA Methylation of Polo-Like Kinase 1 (PLK1) in Colorectal Cancer. Open Journal of Pathology, 2017, 07, 45-57.	0.0	1
474	Identification of Polo-Like Kinase 1 Inhibitors Using Structure-Based Molecular Design. Bulletin of the Korean Chemical Society, 2014, 35, 1929-1930.	1.0	1
475	Polo-like kinase-1 in DNA damage response. BMB Reports, 2014, 47, 249-255.	1.1	48

#	Article	IF	Citations
476	Volasertib (BI 6727), a novel polo-like kinase inhibitor, reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cells. Journal of Cancer Therapeutics & Research, 2013, 2, 13.	1.2	4
477	The molecular docking of 1,4-naphthoquinone derivatives as inhibitors of Polo-like kinase 1 using Molegro Virtual Docker. Journal of Applied Pharmaceutical Science, 0, , .	0.7	15
478	Microarray gene expression profiling in colorectal (HCT116) and hepatocellular (HepG2) carcinoma cell lines treated withMelicope ptelefolialeaf extract reveals transcriptome profiles exhibiting anticancer activity. PeerJ, 2018, 6, e5203.	0.9	16
479	PLK1â€dependent phosphorylation restrains EBNA2 activity and lymphomagenesis in EBVâ€infected mice. EMBO Reports, 2021, 22, e53007.	2.0	5
480	Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer. Molecular Pharmaceutics, 2021, 18, 4448-4458.	2.3	13
481	Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair. Frontiers in Cell and Developmental Biology, 2021, 9, 751574.	1.8	11
482	Ilicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway. Frontiers in Pharmacology, 2021, 12, 723729.	1.6	7
483	Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways. Cell Death and Disease, 2021, 12, 931.	2.7	14
484	Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer. Biomedicine and Pharmacotherapy, 2021, 144, 112347.	2.5	9
485	Virtual Screening of 2-hydroxy-1,4-naphthoquinone Derivatives as Antimitotic Agent using Molegro Virtual Docker on Polo Like Kinase 1. , 0, , .		0
487	Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics. Acta Biomaterialia, 2022, 138, 443-452.	4.1	13
488	Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1. Annals of Translational Medicine, 2020, 8, 1637-1637.	0.7	14
489	Embryonic lethality and defective mammary gland development of activatorâ€function impaired conditional knockâ€in Erbb3^{V943R} mice. Genetics & Genomics Next, 2021, 2, e10036.	0.8	1
491	Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. Cancers, 2021, 13, 5650.	1.7	54
492	A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1. Oncogene, 2022, 41, 372-386.	2.6	10
493	Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Molecules, 2021, 26, 7069.	1.7	4
494	Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer. Cancers, 2021, 13, 5748.	1.7	11
496	The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan. Journal of Cancer, 2022, 13, 728-743.	1.2	7

#	Article	IF	Citations
497	Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. Journal of Medicinal Chemistry, 2022, 65, 1915-1932.	2.9	5
498	A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. Anticancer Research, 2022, 42, 709-722.	0.5	6
499	Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer. Pharmaceutics, 2022, 14, 498.	2.0	6
500	PLK1 Mitigates Intervertebral Disc Degeneration by Delaying Senescence of Nucleus Pulposus Cells. Frontiers in Cell and Developmental Biology, 2022, 10, 819262.	1.8	6
501	Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma. Aging, 2022, 14, 2320-2334.	1.4	7
502	Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle. , 2021, 62, 11.		9
503	The phosphorylation and dephosphorylation switch of VCP/p97 regulates the architecture of centrosome and spindle. Cell Death and Differentiation, 2022, 29, 2070-2088.	5.0	8
507	CircCASC15-miR-100-mTOR may influence the cervical cancer radioresistance. Cancer Cell International, 2022, 22, 165.	1.8	3
508	GATA2-Mediated Transcriptional Activation of Notch3 Promotes Pancreatic Cancer Liver Metastasis. Molecules and Cells, 2022, 45, 329-342.	1.0	3
509	PLK2 targets GSK3Î² to protect against cisplatin-induced acute kidney injury. Experimental Cell Research, 2022, 417, 113181.	1.2	2
510	The functions and effects of CUL3-E3 ligases mediated non-degradative ubiquitination. Gene, 2022, 832, 146562.	1.0	8
511	Shedding light on the binding mechanism of kinase inhibitors BI-2536, Volasetib and Ro-3280 with their pharmacological target PLK1. Journal of Photochemistry and Photobiology B: Biology, 2022, 232, 112477.	1.7	5
512	Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210950.	1.4	0
513	Polo-Like Kinase 2: From Principle to Practice. Frontiers in Oncology, 0, 12, .	1.3	7
514	The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma. Respiratory Research, 2022, 23, .	1.4	7
515	Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential. Journal of Medicinal Chemistry, 2022, 65, 10133-10160.	2.9	34
517	Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy. Cancer Research, 2022, 82, 3532-3548.	0.4	14
518	Effects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines. Frontiers in Genetics, 0, 13, .	1.1	2

#	Article	IF	Citations
519	Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease. Neurobiology of Disease, 2022, 172, 105833.	2.1	3
520	Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma. Frontiers in Genetics, 0, 13, .	1.1	20
521	Hydrophobic Tag Tethering Degradation, The Emerging Targeted Protein Degradation Strategy. Current Medicinal Chemistry, 2023, 30, 3137-3155.	1.2	2
522	The kinase PLK1 promotes the development of Kras / Tp53 -mutant lung adenocarcinoma through transcriptional activation of the receptor RET. Science Signaling, 2022, 15, .	1.6	10
524	Myotubularinâ€Related Protein14 Prevents Neointima Formation and Vascular Smooth Muscle Cell Proliferation by Inhibiting Poloâ€Like Kinase1. Journal of the American Heart Association, 2022, 11, .	1.6	1
525	PLK1 protects intestinal barrier function in sepsis: A translational research. Cytokine, 2023, 162, 156113.	1.4	0
526	Design, synthesis, and biological evaluation of a potent PLK4 inhibitor WY29 with 1Hâ€pyrazolo[3,4â€d]pyrimidine scaffold. Archiv Der Pharmazie, 2023, 356, .	2.1	2
527	Polo-like kinase 1 (PLK1) O-GlcNAcylation is essential for dividing mammalian cells and inhibits uterine carcinoma. Journal of Biological Chemistry, 2023, 299, 102887.	1.6	5
528	Comprehensive Analysis of Necroptosis-Related Genes as Prognostic Factors and Immunological Biomarkers in Breast Cancer. Journal of Personalized Medicine, 2023, 13, 44.	1.1	2
529	<scp>UBAP2L</scp>â€dependent coupling of <scp>PLK1</scp> localization and stability during mitosis. EMBO Reports, 2023, 24, .	2.0	3
530	Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. Pharmaceutics, 2023, 15, 664.	2.0	2
531	Design, synthesis, and biological evaluation of novel dihydropteridone derivatives possessing oxadiazoles moiety as potent inhibitors of PLK1. European Journal of Medicinal Chemistry, 2023, 251, 115242.	2.6	3
532	A comprehensive review on the indazole based derivatives as targeted anticancer agents. Journal of Molecular Structure, 2023, 1284, 135327.	1.8	3
533	Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS. Molecules, 2023, 28, 2550.	1.7	0
534	Extended-sampling QM/MM simulation of biochemical reactions involving Pâ€“N bonds. Physical Chemistry Chemical Physics, 2023, 25, 9824-9836.	1.3	0
535	Phospho PTEN mediated dephosphorylation of mitotic kinase PLK1 and Aurora Kinase A prevents aneuploidy and preserves genomic stability. , 2023, 40, .		1
536	Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers. Frontiers in Oncology, 0, 13, .	1.3	2
553	Chromosome 5. , 2023, , 90-158.		0

#	Article	IF	Citations